Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1997 1
2016 1
2018 1
2021 1
2022 1
2023 4
2024 6
2025 6
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabis-Pedrini MJ, Carroll WM, Lechner-Scott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, Van Pesch V, Laureys G, Willekens B, Prevost J, Foschi M, De Gans K, Horakova D, Havrdova EK, Karabudak R, Patti F, Mccombe PA, Maimone D, Altintas A, Ampapa R, Spitaleri D, Gerlach OHH, Sa MJ, Hughes S, Gouider R, Mrabet S, Macdonell RA, Turkoglu R, Cartechini E, Al-Asmi A, Soysal A, Oh J, Muros-Le Rouzic E, Guye S, Pasquarelli N, Butzkueven H, Jokubaitis VG; MSBase Study Group. Yeh WZ, et al. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200328. doi: 10.1212/NXI.0000000000200328. Epub 2024 Oct 23. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39442037 Free PMC article.
What to Do with the New Antibiotics?
Chaïbi K, Jaureguy F, Do Rego H, Ruiz P, Mory C, El Helali N, Mrabet S, Mizrahi A, Zahar JR, Pilmis B. Chaïbi K, et al. Antibiotics (Basel). 2023 Mar 27;12(4):654. doi: 10.3390/antibiotics12040654. Antibiotics (Basel). 2023. PMID: 37107016 Free PMC article. Review.
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry.
Gomez-Figueroa E, Orozco-Puga P, Corona-Vázquez CP, Moreno-Bernardino C, Elizabeth De la Mora-Landín G, Jiménez-Ruiz A, García-Estrada C, Zertuche-Ortuño L, Saldívar-Dávila S, Rodríguez-Rivas R, Bazán-Rodríguez L, Flores-Rivera J, Kalincik T, Buzzard K, Khoury S, Duquette P, Foschi M, Surcinelli A, Weinstock-Guttman B, Gouider R, Mrabet S, Lechner-Scott J, Butzkueven H, Alroughani R, Roos I, Patti F, Yamout B, Grand'Maison F, Spitaleri D, McCombe P, Luis Sanchez-Menoyo J, Ozakbas S, Al-Asmi A, John N, Cartechini E, Van der Walt A, Garber J, Lapointe E, Soysal A, Aguera-Morales E, Guimarães J, Ruiz-Sandoval JL. Gomez-Figueroa E, et al. Ther Adv Neurol Disord. 2025 Dec 23;18:17562864251399595. doi: 10.1177/17562864251399595. eCollection 2025. Ther Adv Neurol Disord. 2025. PMID: 41466847 Free PMC article.
In search of a function for the Ras-like GTPase Rap1.
Bos JL, Franke B, M'Rabet L, Reedquist K, Zwartkruis F. Bos JL, et al. FEBS Lett. 1997 Jun 23;410(1):59-62. doi: 10.1016/s0014-5793(97)00324-4. FEBS Lett. 1997. PMID: 9247123 Review.
Rap1 (Krev-1) is a small GTPase first identified as a transformation suppressor of K-ras. This GTPase is very similar to Ras, particularly in the effector region, but its function is still elusive. ...
Rap1 (Krev-1) is a small GTPase first identified as a transformation suppressor of K-ras. This GTPase is very similar to Ras, particu …
Causal effects of multiple sclerosis therapies in left-truncated registry data.
Haile DC, Diouf I, Ozakbas S, Horakova D, Havrdova EK, Patti F, Eichau S, Alroughani R, Lugaresi A, Tomassini V, Prat A, Girard M, Terzi M, Yamout B, Khoury SJ, Grammond P, Blanco Y, Shaygannejad V, Foschi M, Surcinelli A, Neri S, Weinstock-Guttman B, Prevost J, Amato MP, Barnett M, Gerlach O, John N, Kermode AG, Fabis-Pedrini M, Carroll WM, van der Walt A, Butzkueven H, van Pesch V, Soysal A, Gouider R, Mrabet S, Spitaleri D, Cartechini E, Maimone D, Ampapa R, Laureys G, Ramo-Tello C, Di Gregorio M, Lapointe E, Slee M, Karabudak R, Garber J, Altintas A, Hodgkinson S, Sanchez-Menoyo JL, Castillo-Triviño T, Habek M, Al-Asmi A, Al-Harbi T, Csepany T, Cárdenas-Robledo S, Taylor B, Foong YC, Willekens B, Shalaby N, Moore F, McGuigan C, Baghbanian SM, Massey J, Hardy TA, Ramanathan S, Gross-Paju K, Gray O, Decoo D, Shaw C, Simu M, Rozsa C, Stuart EA, Sharmin S, Roos I, Kalincik T. Haile DC, et al. Mult Scler. 2026 Sep;32(10):1052-1068. doi: 10.1177/13524585261459943. Epub 2026 Jul 21. Mult Scler. 2026. PMID: 42479470 Free PMC article.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez MM, Ozakbas S, Horakova D, Havrdova EK, Patti F, Alroughani R, Izquierdo G, Eichau S, Boz C, Zakaria M, Onofrj M, Lugaresi A, Weinstock-Guttman B, Prat A, Girard M, Duquette P, Terzi M, Amato MP, Karabudak R, Grand'Maison F, Khoury SJ, Grammond P, Lechner-Scott J, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Turkoglu R, Altintas A, Maimone D, Kermode A, Shalaby N, Pesch VV, Butler E, Sidhom Y, Gouider R, Mrabet S, Gerlach O, Soysal A, Barnett M, Kuhle J, Hughes S, Sa MJ, Hodgkinson S, Oreja-Guevara C, Ampapa R, Petersen T, Ramo-Tello C, Spitaleri D, McCombe P, Taylor B, Prevost J, Foschi M, Slee M, McGuigan C, Laureys G, Hijfte LV, de Gans K, Solaro C, Oh J, Macdonell R, Aguera-Morales E, Singhal B, Gray O, Garber J, Wijmeersch BV, Simu M, Castillo-Triviño T, Sanchez-Menoyo JL, Khurana D, Al-Asmi A, Al-Harbi T, Deri N, Fragoso Y, Lalive PH, Sinnige LGF, Shaw C, Shuey N, Csepany T, Sempere AP, Moore F, Decoo D, Willekens B, Gobbi C, Massey J, Hardy T, Parratt J, Kalincik T. Sharmin S, et al. Brain. 2023 Nov 2;146(11):4633-4644. doi: 10.1093/brain/awad218. Brain. 2023. PMID: 37369086 Free PMC article.
Unlocking the potential of Opuntia species mucilage in chemistry.
Del Mar García Martín C, Ramírez O, Bonardd S, López-Darias M, Franco L, M'Rabet Y, Khwaldia K, Díaz Díaz D. Del Mar García Martín C, et al. Int J Biol Macromol. 2024 May;268(Pt 2):131647. doi: 10.1016/j.ijbiomac.2024.131647. Epub 2024 Apr 21. Int J Biol Macromol. 2024. PMID: 38653432 Free article.
Synthesized AuNP/mucilage was evaluated as a plasmonic catalyst for the reduction of 4-nitrophenol as model reaction, showing a considerable enhancement in its k(app) of 97 % under white light and a decrease of 24.8 % in its activation energy....
Synthesized AuNP/mucilage was evaluated as a plasmonic catalyst for the reduction of 4-nitrophenol as model reaction, showing a considerable …
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Daruwalla C, Shaygannejad V, Ozakbas S, Havrdova EK, Horakova D, Alroughani R, Boz C, Patti F, Onofrj M, Lugaresi A, Eichau S, Girard M, Prat A, Duquette P, Yamout B, Khoury SJ, Sajedi SA, Turkoglu R, Altintas A, Skibina O, Buzzard K, Grammond P, Karabudak R, van der Walt A, Butzkueven H, Maimone D, Lechner-Scott J, Soysal A, John N, Prevost J, Spitaleri D, Ramo-Tello C, Gerlach O, Iuliano G, Foschi M, Ampapa R, van Pesch V, Barnett M, Shalaby N, D'hooghe M, Kuhle J, Sa MJ, Fabis-Pedrini M, Kermode A, Mrabet S, Gouider R, Hodgkinson S, Laureys G, Van Hijfte L, Macdonell R, Oreja-Guevara C, Cristiano E, McCombe P, Sanchez-Menoyo JL, Singhal B, Blanco Y, Hughes S, Garber J, Solaro C, McGuigan C, Taylor B, de Gans K, Habek M, Al-Asmi A, Mihaela S, Castillo Triviño T, Al-Harbi T, Rojas JI, Gray O, Khurana D, Van Wijmeersch B, Grigoriadis N, Inshasi J, Oh J, Aguera-Morales E, Fragoso Y, Moore F, Shaw C, Baghbanian SM, Shuey N, Willekens B, Hardy TA, Decoo D, Sempere AP, Field D, Wynford-Thomas R, Cunniffe NG, Roos I, Malpas CB, Coles AJ, Kalincik T, Brown JWL. Daruwalla C, et al. Mult Scler. 2023 Jun;29(7):875-883. doi: 10.1177/13524585231151951. Epub 2023 Feb 27. Mult Scler. 2023. PMID: 36851894 Free PMC article.
Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
Zeineddine M, Al-Roughani R, Farouk Ahmed S, Khoury S, El-Ayoubi N, Al-Mahdawi A, Al-Khabouri J, Al-Asmi A, Chentouf A, Inshasi J, Gouider R, Mrabet S, Shalaby N, Massouh J, Mohamed Ramzy Hasan Mohamed F, Al-Hajje A, Salameh P, Dimassi H, Boumediene F, Yamout B. Zeineddine M, et al. Mult Scler. 2024 Jul;30(8):1026-1035. doi: 10.1177/13524585241261565. Epub 2024 Jul 26. Mult Scler. 2024. PMID: 39054846
Spontaneous facial hematoma induced by vitamin K antagonist therapy: a rare case report.
Mrabet A, Boulouiz S, Bilal M, El Ouafi N, Bazid Z. Mrabet A, et al. Ann Med Surg (Lond). 2023 Apr 3;85(4):1141-1144. doi: 10.1097/MS9.0000000000000358. eCollection 2023 Apr. Ann Med Surg (Lond). 2023. PMID: 37113896 Free PMC article.
The benefits of anti-vitamin K drugs have been demonstrated in several indications; however, it is always counterbalanced by an increased risk of bleeding, that can occur in different areas. Facial hematoma is a rare bleeding complication to our knowledge, this is the firs …
The benefits of anti-vitamin K drugs have been demonstrated in several indications; however, it is always counterbalanced by an incre …
25 results